Treats metastatic carcinoid tumors. ANDA 204669, held by Heritage. Octreotide Acetate.
As of Nov 16, 2026, ANDA 204669 (Octreotide Acetate), held by Heritage, was first approved by FDA on Dec 27, 2018, with 4 approved supplements and 0 published complete response letters.
Octreotide acetate injection is a somatostatin analogue indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 27, 2018 | Original application | Approved | None posted |
| Octreotide AcetateEQ 0.05MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 0.1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 0.5MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Jul 9, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 3, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 27, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters